Comparison of naveibine and cisplatin versus gemcitabine and cisplatin in refractory metastatic breast cancer / 肿瘤研究与临床
Cancer Research and Clinic
; (6)1999.
Artigo
em Chinês
| WPRIM (Pacífico Ocidental)
| ID: wpr-676401
Biblioteca responsável:
WPRO
ABSTRACT
0.05).The degreeⅢ~Ⅳthrombocytopenia was more common in group A than in group B,but the degreeⅢ~Ⅳhypolekocytosis and phlebitis was more serious in group B.Conclusion NC and GC for treating refractory metastatic breast cancer have a high response rate and tolerable side effects.
Texto completo:
Disponível
Base de dados:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
Cancer Research and Clinic
Ano de publicação:
1999
Tipo de documento:
Artigo